Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 73 results found. Search for [ bharat biotech covaxin phase 3 results ]

Results 1 to 21 of 73
BusinessToday.In
June 3, 2021
The Union Health Ministry will make an advance payment of Rs 1,500 crore to Hyderabad-based drugmaker Biological-E for what will be the second made-in-India vaccine following Bharat Biotech's Covaxin


PTI
May 25, 2021
Ocugen has submitted key information and data to date including preclinical studies, chemistry, manufacturing, and controls (CMC), and clinical studies as a Master File for FDA review and input prior to a planned EUA submission


Joe C Mathew
April 21, 2021
\"Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use,\" said Dr Krishna Ella, MD & Chairman, Bharat Biotech


BusinessToday.In
April 21, 2021
The ICMR has said that the vaccine developed by Bharat Biotech is effective against the UK and Brazil variants of SARS-CoV-2 and the double mutant strain of the virus


BusinessToday.In
April 13, 2021
Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev added that Sputnik V's production at a larger scale will start by July 2021 with plans to produce 500 million doses


BusinessToday.In
March 9, 2021
The most common adverse event in the phase 2 trial was pain at the injection site, followed by headache, fatigue, and fever.


BusinessToday.In
New Delhi, March 4, 2021
IT major Infosys on Wednesday said it will cover the vaccination cost for its employees in India and their family members; Bharat Biotech has announced the Phase 3 clinical trial results for its coronavirus vaccine candidate Covaxin; The COVAX initiative, co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), will supply 237 million doses of the AstraZeneca-Oxford COVID-19 vaccine to 142 countries by May-end. Watch this and more on News Blast.Also Read: Canada receives first shipment of 5 lakh COVID-19 vaccine doses from Serum Institute


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


Reuters
March 4, 2021
Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said


Rashi Bisaria
New Delhi, March 4, 2021
Digital media norms to be administered by Centre, not states The Information and Broadcasting (I&B) Ministry on Wednesday issued memorandum to states and union territories saying that the new rules for digital news publishers and over-the-top (OTT) platforms are to be administered by the Centre, not the states. The government had notified the Information Technology (Intermediary Guidelines and Digital Media Ethics Codes) Rules, 2021 on February 25. Defence equipment sales to India sho...


BusinessToday.In
March 4, 2021
Very early this morning, our first half a million doses of the AstraZeneca-Oxford vaccine from the Serum Institute arrived in Canada, said Prime Minister Justin Trudeau


PB Jayakumar
March 3, 2021
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy


BusinessToday.In
March 3, 2021
Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report


BusinessToday.In
March 3, 2021
Meanwhile, consulting and processing services provider Accenture also said that it will cover the cost for employees and dependents eligible for vaccination.


Joe C Mathew
March 3, 2021
The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR


BusinessToday.In
March 3, 2021
Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India


BusinessToday.In
March 2, 2021
As senior citizens across the country take part in the vaccination drive, here is all the information they need two know about the two vaccines - Covaxin and Covishield


Joe C Mathew
February 19, 2021
Coronavirus vaccine: The Covid-19 vaccine candidate of Novavax is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom


BusinessToday.In
February 12, 2021
Chhattisgarh CM had raised two primary concerns regarding Covaxin -- inhibitions on incomplete trials and absence of \"expiration date\". Dr Vardhan says vaccine approved after due evaluation of pre-clinical and clinical trial data and that expiry date is mentioned on its label


BusinessToday.In
January 30, 2021
Serum Institute of India CEO Adar Poonawalla said the company's tie-up with American vaccine developer Novavax has published 'excellent efficacy results'


PAGES 1 OF 4  1234